Immune independent crosstalk between lymphoma and myeloid suppressor CD14⁺HLA-DR^low/negmonocytes mediates chemotherapy resistance

Intratumoral CD14+ Cells and Circulating CD14+HLA-DRlo/neg Monocytes Correlate with Decreased Survival in Patients with Clear Cell Renal Cell Carcinoma

“…Perhaps by targeting these cells through elimination or blocking their migration to tumors, the efficacy of conventional therapies will likely improve. For example, we have recently shown that in a similar in vitro model with non-Hodgkin lymphomas, the presence of monocytes protected the tumor from direct killing with doxorubicin by altering the expression patterns of proapoptotic and antiapoptotic proteins (38). This study identifies an additional mechanism, protection from chemotherapy-induced cytotoxicity, in which the interaction of monocytes and tumor cells reduces the efficacy of anticancer treatments.…”

Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies

“…MDSCs are rare in lymph nodes [8], but they can affect lymphocyte trafficking and antigen-induced priming by reducing the expression of homing receptors on naïve T- and B-cells [31,32,33,34] to restrict antigen-driven expansion of both T- and B-cells [18], an effect reverted by gemcitabine-based chemotherapy [31]. MDSCs are increased in several lymphoma subtypes and are associated with a poor clinical outcome, probably due to enhanced chemotherapy resistance as shown by preclinical models [35,36].…”

Serum protein profiling in diffuse large B‐cell lymphoma

“…CD14 is a myeloid differentiation marker expressed primarily on monocytes/macrophages. Recently, it was shown that NHL patients with a more aggressive disease phenotype exhibited high expression of CD14 and low expression of HLA‐DR (CD14 + HLA‐DR − /low) that suppresses normal immune function and the proliferation of normal T‐cells . Moreover, lymphoma cells treated with CD14 + HLA‐DR − /low monocytes exhibited chemotherapeutic resistance to doxorubicin.…”